For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Nootropic & Cognitive · Comparison

Dihexa vs Pinealon

A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

DihexaPinealon
CategoryNootropic & CognitiveNootropic & Cognitive
Also known asPNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amideEDR, Glu-Asp-Arg, Pineal tripeptide
EvidencePreclinical onlyResearch-stage
Dosing range10mg–20mg mg, Once daily (or every other day — long-lasting effects)100mcg–300mcg mcg, Once daily (evening, given melatonin/sleep effects)
AdministrationOral (capsule), Transdermal (cream/lotion — lipophilicity makes this effective), Subcutaneous injection (less common)Subcutaneous injection, Intranasal, Oral (sublingual for better absorption)
Key side effectsPotential for pro-proliferative effects — HGF/c-Met pathway promotes cell growth (theoretical cancer concern at high doses), Headache (uncommon), Mental fatigue if overdosed, Long half-life means effects accumulate — take every other day initiallyGenerally well-tolerated, Drowsiness if dosed during the day, Vivid dreams (common — melatonin pathway activation), Mild headache (uncommon)
Cited sources2 references2 references

Key differences

  • Evidence level differs: Dihexa is preclinical only, while Pinealon is research-stage.
  • Administration: Dihexa — Oral (capsule), Transdermal (cream/lotion — lipophilicity makes this effective), Subcutaneous injection (less common); Pinealon — Subcutaneous injection, Intranasal, Oral (sublingual for better absorption).
  • Dosing units differ: Dihexa is dosed in mg, Pinealon in mcg — they operate at different scales.
  • Frequency: Dihexa is typically Once daily (or every other day — long-lasting effects); Pinealon is Once daily (evening, given melatonin/sleep effects).

How each works

Dihexa

Dihexa (PNB-0408) was developed by Joseph Harding and colleagues at WSU as a metabolically stable angiotensin IV analog. It binds hepatocyte growth factor (HGF), potentiating its interaction with the c-Met receptor — a pathway critical for dendritic branching, synapse formation, and synaptic plasticity. In rodent Alzheimer's and scopolamine-impaired models, Dihexa restored cognitive performance at doses ~7 orders of magnitude lower than BDNF. It readily crosses the blood-brain barrier due to its lipophilicity, unlike BDNF itself.

Pinealon

Like other peptide bioregulators from the Khavinson group, Pinealon is proposed to work by penetrating the nuclear membrane and interacting directly with histones and promoter regions to regulate transcription. In vitro studies show Pinealon increases synthesis of serotonin and melatonin precursors in pinealocytes and upregulates antioxidant enzyme expression in neuronal cells. Animal studies demonstrate reduced neuronal apoptosis after hypoxic stress and improved performance in cognitive tasks. Clinical observations from Russian gerontology practice suggest benefits for insomnia, age-related cognitive decline, and neurological recovery.

Read the full Dihexa profileRead the full Pinealon profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.